Patient Stories: Real Experiences with Castle Biosciences Testing
Turning an uncertain diagnosis into an empowered plan
Meet Kenna, a cancer survivor, wife, and mother of six. After hitting her head at work, she noticed an arc of light in her vision and assumed a minor retinal issue — until her doctor told her she had a tumor. Later that day, an email confirming her follow-up appointment carried an unfamiliar phrase: choroidal melanoma.
The peace of mind that comes from a low-risk result TissueCypher result
Meet Carrie, a cancer survivor who was working through some gastroenterology issues. Following an upper endoscopy, her gastroenterologist informed her that she had non-dysplastic Barrett’s esophagus, a condition that carries a risk of esophageal cancer.
.jpg)
The missing piece that helped Heidi make the case for her own ocular melanoma care
Meet Heidi, a cancer survivor from South Carolina. She first noticed something was wrong when she covered her left eye and realized she could barely see out of it. What her optometrist first suspected was a detached retina turned out to be a large ocular melanoma.
The knowledge that helps Danny stay a step ahead of a hereditary cancer
Meet Danny, a cancer survivor from Roxboro, North Carolina. In 2017, his optometrist noted a freckle in his right eye and said they’d simply keep an eye on it. By his 2021 visit, it had changed — and his doctor referred him to Duke Eye Center, where he was diagnosed with a small ocular melanoma.
The benefit of an early warning
Hear how they navigated Craig's diagnosis of BE and the impact that risk stratification with TissueCypher had on his care. Craig’s test results were an early warning that he was at high risk of progression, which enabled his care team to intervene and make critical decisions that helped him avert a future esophageal cancer diagnosis
.jpg)
Melanoma Changed My Life at 26 | Leah's Story of Survival, Family, and Hope
It's melanoma, now what?
Melanoma is one of the most common cancers found among adults, aged 15-29, in the U.S. and the deadliest if not caught early. There are emerging technologies to help identify a patient’s risk for recurrence and metastasis such as gene expression profiling. Learn about DecisionDX-Melanoma, which is a predictive test to help patients make the most informed treatment decisions.
.jpg)
From uncertainty to reassurance: Robin’s TissueCypher story
Meet Robin Byrd Wilfong. She was familiar with Barrett’s esophagus due to her family history, but after her own diagnosis, she wanted a clearer understanding of her personal risk of progression. Determined to take an active role in her care, Robin became her own health advocate—researching her condition and asking the right questions, which ultimately led her to TissueCypher.
From Fear to Confidence: DecisionDx-Melanoma. Greg’s Story of Empowerment Over a Melanoma Diagnosis
Discover Greg’s inspiring journey from a cancer diagnosis to a life of outdoor adventures, empowered by the DecisionDx-Melanoma test. Follow his path to knowledge and resilience in the face of melanoma.
From diagnosis to determination: Don's skin cancer journey of hope, clarity and a plan
Don Jaeger's story is a powerful reminder that with early dectection and the right information, cancer doesn't have to be a life altering fear
Facing Melanoma: Leah B's Journey from PA to Patient
Leah never imagined she’d go from treating patients to becoming one. Just five days after her wedding, she received a life-changing call—she had melanoma. With countless questions about her future, she turned to DecisionDx-Melanoma for answers. Her test results provided clarity, helping her avoid unnecessary surgeries and find peace of mind. Watch her inspiring journey of resilience, hope, and the power of knowing.
Don't let fear define your journey: a uveal melanoma patient journey
Danet didn’t let fear of the unknown define her uveal melanoma journey. Hear how Castle Biosciences DecisionDx-UM test impacted her treatment.
.jpg)
Choosing knowledge as a source of strength, even when the result wasn’t what she hoped
Meet Kristie, a chiropractor from Greenville, South Carolina, who spent months attributing her visual disturbances to migraines — until vision loss in one eye led to anurgent diagnosis: a large melanoma that had already detached her retina. Her care team gave her a brochure for Castle Biosciences’ DecisionDx-UM test.
Be your own advocate: Morgan England, Stage III melanoma survivor, shares her story
As a Stage III Melanoma survivor, Morgan speaks on how important it is to be your own advocate. After her diagnosis, she requested the DecisionDx-Melanoma test from her doctor for the additional information it can provide. The results she received from her DecisionDx-Melanoma test report continue to help reduce her anxiety and provide confidence about her future.
.jpg)
A TissueCypher high-risk result provides confidence and clarity for the path forward
Johnny Walker’s diagnosis with Barrett's esophagus (BE) came as a surprise while he was being treated for another GI issue. Fortunately, his gastroenterologist routinely orders the TissueCypher risk stratification test on all patients diagnosed with non-dysplastic BE. The results came back “high-risk” with a 14% chance of progression in the next 5 years. Both Johnny and his GI were thankful for the early warning.
.jpg)
A reassuring result that fuels her role as her own advocate
Meet Patricia, a cancer survivor who grew up in Philadelphia and later relocated to Virginia. A routine eye exam turned up what her doctor described as a large freckle; three months later, it had become a tumor, and she was referred to a retina specialist.
A life-changing prognosis of uveal melanoma: Kevin’s story
After being diagnosed with uveal (or ocular) melanoma, Kevin was directed to explore the benefits and indications of Castle Biosciences' DecisionDx-UM gene expression profile (GEP) test, which predicts a patient’s risk based upon their tumor’s own unique biology. The findings of the test, Kevin says, "were of huge importance to myself and my family. They put me at rest and we could all move on. The Castle's uveal melanoma prognostic platform can truly be life-changing."